Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study)

Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study)

Introduction Sickle cell disease (SCD) is one of the most common genetic diseases in the world, annually affecting approximately 310 000 births and causing >100 000 deaths. Vaso-occlusive crisis (VOC) is the most frequent complication of SCD, leading to bone pain, thoracic pain (acute chest s...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas Agoritsas, Alain Gervaix, Sylvain Boet, Pierre Cougoul, Cyril Sahyoun, Jerôme Stirnemann, Benoît Desgraz, Olivier Grosgurin, Jean-Luc Reny, Jacques Serratrice, Yves Chalandon, Marc Ansari, Pierre Louge, Tamara Mann, Combescure Christophe, Kaveh Samii, Rodrigue Pignel, Giovanna Cannas, Laurent Cimasoni, Thierry Joffre, Claude Lae, Marie-Anne Magnan, Etienne Menager, Annie Momo Bona, Marc-Alain Panchard, Michel Pellegrini, Beatrice Riu
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/11/e084825.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/11/e084825.full

Similar Items